Association between lncrna PCGEM1 polymorphisms and prostate cancer risk

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 2, 2013, Pages 139-144

  Xue, Y ^a   Wang, M ^a   Kang, M ^a   Wang, Q ^a   Wu, B ^a   Chu, H ^a   Zhong, D ^a   Qin, C ^b   Yin, C ^b   Zhang, Z ^a   Wu, D ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

genetic susceptibility; molecular epidemiology; PCGEM1; urological tumor

Indexed keywords

LONG UNTRANSLATED RNA; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER RISK; CARCINOGENESIS; CHINESE; CONTROLLED STUDY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PCGEM1 GENE; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

AGED; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS; RNA, LONG NONCODING;

EID: 84882448188     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.6     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004; 108: 130-135. (Pubitemid 37444455)
3. Shao Q, Ouyang J, Fan Y, Xie J, Zhou J, Wu J et al. Prostate cancer in the senior men from rural areas in east district of China: contemporary management and 5-year outcomes at multi-institutional collaboration. Cancer Lett 2012; 315: 170-177.
4. Isaacs W, De Marzo A, Nelson WG. Focus on prostate cancer. Cancer Cell 2002; 2: 113-116. (Pubitemid 41039111)
5. Dianat SS, Margreiter M, Eckersberger E, Finkelstein J, Kuehas F, Herwig R et al. Gene polymorphisms and prostate cancer: the evidence. BJU Int 2009; 104: 1560-1572.
6. Moran VA, Perera RJ, Khalil AM. Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res 2012; 40: 6391-6400.
7. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009; 10: 155-159.
8. Costa FF. Non-coding RNAs: Meet thy masters. Bioessays 2010; 32: 599-608.
9. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009; 23: 1494-1504.
10. Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? Hum Mol Genet 19: R152-R161.
11. Ifere GO, Ananaba GA. Prostate cancer gene expression marker 1 (PCGEM1): a patented prostate- specific non-coding gene and regulator of prostate cancer progression. Recent Pat DNA Gene Seq 2009; 3: 151-163.
12. Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 2004; 23: 605-611. (Pubitemid 38175016)
13. Fu X, Ravindranath L, Tran N, Petrovics G, Srivastava S. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol 2006; 25: 135-141.
14. Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci USA 2000; 97: 12216-12221.
15. Jin G, Sun J, Isaacs SD, Wiley KE, Kim ST, Chu LW et al. Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. Carcinogenesis 2011; 32: 1655-1659.
16. Chen J, Wu Y, Shao P, Cao Q, Qin C, Li P et al. Association between VHL single nucleotide polymorphism (rs779805) and the susceptibility to prostate cancer in Chinese. DNA Cell Biol 2011; 31: 790-796.
17. Wang M, Liu F, Hsing AW, Wang X, Shao Q, Qi J et al. Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: a case-control study in the ChinaPCa consortium. Carcinogenesis 2012; 33: 356-360.
18. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80. (Pubitemid 350166735)
19. Rohrmann S, Linseisen J, Allen N, Bueno-de-Mesquita HB, Johnsen NF, Tjonneland A et al. Smoking and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2012; 108: 708-714.
20. Zuccolo L, Lewis SJ, Donovan JL, Hamdy FC, Neal DE, Smith GD. Alcohol consumption and PSA-detected prostate cancer risk-A case-control nested in the ProtecT study. Int J Cancer 2012; 132: 2176-2185.
21. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265. (Pubitemid 40202029)
22. Bialkowska-Hobrzanska H, Driman DK, Fletcher R, Harry V, Razvi H. Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue. Can J Urol 2006; 13: 2967-2974.
23. Verhaegh GW, Verkleij L, Vermeulen SH, den Heijer M, Witjes JA, Kiemeney LA. Polymorphisms in the H19 gene and the risk of bladder cancer. Eur Urol 2008; 54: 1118-1126.
24. Liu Y, Pan S, Liu L, Zhai X, Liu J, Wen J et al. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. PLoS ONE 2012; 7: e35145.
25. Ishii N, Ozaki K, Sato H, Mizuno H, Saito S, Takahashi A et al. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet 2006; 51: 1087-1099. (Pubitemid 44800728)
26. Schulz WA, Burchardt M, Cronauer MV. Molecular biology of prostate cancer. Mol Hum Reprod 2003; 9: 437-448. (Pubitemid 36874302)
27. Amanatullah DF, Reutens AT, Zafonte BT, Fu M, Mani S, Pestell RG. Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Front Biosci 2000; 5: D372-D390.
28. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999; 97: 527-538. (Pubitemid 29231175)
29. Young CY, Montgomery BT, Andrews PE, Qui SD, Bilhartz DL, Tindall DJ. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 1991; 51: 3748-3752.
30. Huang CL, Yang CH, Yeh KH, Hu FC, Chen KY, Shih JY et al. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer 2009; 64: 346-351.
31. Wu D, Tian Y, Gong W, Zhu H, Zhang Z, Wang M et al. Genetic variants in the Runtrelated transcription factor 3 gene contribute to gastric cancer risk in a Chinese population. Cancer Sci 2009; 100: 1688-1694.
32. Nasiri M, Saadat I, Omidvari S, Saadat M. Genetic variation in DNA repair gene XRCC7 (G6721T) and susceptibility to breast cancer. Gene 2012; 505: 195-197.
33. Ban Y, Tozaki T, Taniyama M, Skrabanek L, Nakano Y, Ban Y et al. Multiple SNPs in intron 41 of thyroglobulin gene are associated with autoimmune thyroid disease in the Japanese population. PLoS ONE 2012; 7: e37501.
34. Kereszturi E, Kiraly O, Sahin-Toth M. Minigene analysis of intronic variants in common SPINK1 haplotypes associated with chronic pancreatitis. Gut 2009; 58: 545-549.
35. Choi JW, Park CS, Hwang M, Nam HY, Chang HS, Park SG et al. A common intronic variant of CXCR3 is functionally associated with gene expression levels and the polymorphic immune cell responses to stimuli. J Allergy Clin Immunol 2008; 122: 1119-1126 e1117.